Elanco Animal Health Incorporated
NYSE•ELAN
CEO: Mr. Jeffrey N. Simmons
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2018-09-20
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
連絡先情報
時価総額
$11.81B
PER (TTM)
-48.6
32.2
配当利回り
--
52週高値
$27.72
52週安値
$11.92
52週レンジ
順位55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q1 2026 データ
売上高
$1.37B+0.00%
直近4四半期の推移
EPS
$0.11+0.00%
直近4四半期の推移
フリーCF
-$38.00M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Grows Six Percent Total revenue reached $4,715M in 2025, marking a 6% increase driven by volume and pricing across segments.
Gross Margin Remains Flat Gross profit increased 6% to $2,593M; gross margin percentage held steady at 55.0% versus 54.9% in 2024.
Debt Profile Improved Total debt decreased to $3,762M by year-end 2025 following October refinancing activities and significant repayments.
New Products Drive Volume Higher volumes driven by new products like Credelio Quattro and Zenrelia contributed to Pet Health revenue growth.
リスク要因
Significant Net Loss Recorded Reported net loss of ($232)M in 2025 contrasts sharply with $338M income reported in the prior fiscal year.
Restructuring Costs Increase Asset impairment and restructuring charges rose 58% to $237M, reflecting costs from the authorized 2025 Restructuring Plan.
Intense Industry Competition Highly competitive animal health industry faces pressure from generic products and potential pricing power erosion.
Manufacturing and Supply Risks Operations face risks from manufacturing capacity imbalances, potential shortages, and regulatory scrutiny on antibiotic use.
見通し
Executing 2025 Restructuring Plan Plan targets margin expansion and footprint optimization, expecting $25M savings in 2026 from facility closures.
Farm Animal Portfolio Growth Anticipate launching Befrena in Q2 2026; subsequent event includes acquiring AHV to boost cattle product portfolio.
Continued R&D Investment R&D expenses increased 7% to $368M, supporting pipeline development via internal efforts, partnerships, and acquisitions.
Capital Spending Forecast Anticipate 2026 capital expenditures between $175M and $200M, following $276M spent in 2025 for facility expansion.
同業比較
売上高 (TTM)
$45.08B
$14.56B
$6.07B
粗利益率 (最新四半期)
98.3%
96.7%
74.6%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| RVMD | $30.15B | -20.5 | -83.2% | 7.0% |
| MRNA | $21.57B | -6.7 | -36.7% | 11.3% |
| VTRS | $19.99B | -66.9 | -2.0% | 38.9% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.4%
緩やかな成長
4四半期純利益CAGR
73.0%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月13日
EPS:$0.35
|売上高:$1.27B
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし